Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Following CAR-T pioneers' footsteps, Tessa launches China JV in $120M deal

6 years ago

R&D leader Vertex executes a $420M cash gambit to dominate gene editing field for Duchenne MD

6 years ago

Ned Sharpless weighs in on gene therapy pricing debate, suggesting 'the messaging got lost'

6 years ago

EU stamps historic OK on bluebird’s gene therapy for β-thalassemia — now sit back and wait for the price

6 years ago

Atara brings on Novartis vet to replace founder Ciechanover as chief

6 years ago

Novartis rolls out its next big drug at a record-setting price of $2.12M — let the gene therapy pricing debate begin

6 years ago

Another gene therapy company launches with VC cash and a CRISPR tech to target toxic RNA

7 years ago

David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal

7 years ago

Cancer research groups urge FDA to overhaul standards for early cell therapy trials, cutting time and cost. But will 'pre-competitive' alliances fly?

7 years ago

Regulatory intelligence: Update on regenerative medicine advanced therapies designations

7 years ago

Solid Bio’s higher gene therapy dose for Duchenne MD runs smack into a fresh set of safety issues -- shares tumble

7 years ago

Bayer kicks off a $150M add-on for its campus in Berkeley

7 years ago

Sarepta goes back to the gene therapy well at Nationwide Children’s for its latest muscle-wasting program

7 years ago

Rattle and hum: Roche, PTC post update on their SMA drug as a shaken Biogen faces yet another franchise buster

7 years ago

One of the world's top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field

7 years ago

New Zolgensma data suggest comparable efficacy to Spinraza — analysts

7 years ago

Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

7 years ago

Top 20 players: Everybody loves an orphan — especially when they come with blockbuster sales and a long run of exclusivity

7 years ago

As safety looms larger in CAR-T research, study highlights how small tweaks can make it easier to use

7 years ago

Watch out bluebird bio. A little biotech just got Novartis’ backing to break out of the back field and race you to the finish line with a BCMA CAR-T

7 years ago

Novartis' star gene therapy faces potential safety issue following a recent infant death in study

7 years ago

Gene therapy for 'bubble boy disease' sets stage for cure

7 years ago

In another CRISPR first, Penn researchers dose US cancer patients with gene-edited T cell therapy

7 years ago

Adverum Bio offers a late notification about FDA hold on lead gene therapy for wet AMD

7 years ago

First page Previous page 51 52 535455 56 57 Next page Last page